A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Seagen Inc.
Seagen Inc.
Eli Lilly and Company
Pheon Therapeutics
Kivu Bioscience Inc.
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Bristol-Myers Squibb
Jazz Pharmaceuticals
Revolution Medicines, Inc.
Pfizer
Actuate Therapeutics Inc.
Alterome Therapeutics, Inc.
EMD Serono
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Institut Paoli-Calmettes
RasCal Therapeutics, Inc.
Frontier Medicines Corporation
Filamon LTD
Tomsk National Research Medical Center of the Russian Academy of Sciences
NeoImmuneTech
Hoffmann-La Roche
ViroMissile, Inc.
University of California, Davis
Massachusetts General Hospital
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Duke University
A2 Biotherapeutics Inc.
AstraZeneca
Arvinas Inc.
Tasca Therapeutics
Essen Biotech
National Institutes of Health Clinical Center (CC)
MBrace Therapeutics
Azienda Ospedaliero-Universitaria di Parma
Revolution Medicines, Inc.
Poseida Therapeutics, Inc.
MacroGenics
Poitiers University Hospital